OptimizeRx (OPRX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue increased 36% year-over-year to $18.8 million, driven by DAAP sales growth and the Medicx Health acquisition, with gross margin improving to 62.2% and positive cash flow from operations.

• Net loss for Q2 2024 was $4.0 million ($0.22 per share), slightly improved from Q2 2023, while non-GAAP net income was $0.3 million and Adjusted EBITDA turned positive at $0.5 million.

• Strong DAAP adoption with eight deals closed in Q2 and a $6 million multi-brand program delayed to the second half of 2024 due to client approval timing.

• Focus on converting over 300 supported brands to DAAP and expanding enterprise-level engagements for more consistent, recurring revenue.

• Operating expenses rose 22% year-over-year in Q2 2024, mainly due to increased headcount and integration costs from the Medicx Health acquisition.

Financial highlights

• Q2 2024 net revenue was $18.8 million (+36% YoY), with gross profit of $11.7 million (62.2% margin), and net loss of $4.0 million ($0.22/share).

• Non-GAAP net income was $0.3 million, and Adjusted EBITDA was a $0.5 million gain, both improved from prior year.

• Cash and equivalents at June 30, 2024, were $15.0 million; net cash from operations for the first half of 2024 was $2.9 million.

• Debt principal stood at $37.3 million after repayments post-Medicx acquisition.

• Working capital as of June 30, 2024, was $31.0 million, with a current ratio of 3.1:1.

Outlook and guidance

• Full-year 2024 guidance reiterated: revenue expected to be at least $100 million and Adjusted EBITDA at least $11 million.

• Expectation to complete the delayed $6 million DAAP deal in Q3, with revenue recognition in the second half of 2024.

• Over 80% revenue visibility for the full year, with $15 million in additional sales needed to meet guidance.

• Management expects funds from operations and existing cash to be sufficient for the next 12 months.

• Seasonality expected, with 25-30% of annual revenue in Q3 and the remainder in Q4.